Comparative Pharmacology
Head-to-head clinical analysis: LYSTEDA versus TRASYLOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LYSTEDA versus TRASYLOL.
LYSTEDA vs TRASYLOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibition of plasminogen activation, reducing fibrinolysis.
Aprotinin is a serine protease inhibitor that forms reversible enzyme-inhibitor complexes with trypsin, plasmin, kallikrein, and chymotrypsin, thereby inhibiting fibrinolysis and reducing perioperative blood loss.
650 mg orally three times daily (total 3.9 g/day) for up to 5 days during menses.
1,000,000 KIU (kallikrein inhibitor units) IV loading dose over 10 minutes, followed by 250,000 KIU/hour continuous IV infusion during surgery; also 1,000,000 KIU added to cardiopulmonary bypass circuit prime volume.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours (range 1.5–2.5 hours). In patients with renal impairment, half-life is significantly prolonged (up to 20 hours in severe renal impairment).
Terminal elimination half-life approximately 2 hours (alpha phase) and 10-12 hours (beta phase); prolongation in renal impairment.
Primarily renal excretion (>95% unchanged drug via glomerular filtration). Less than 5% is metabolized (mainly acylated derivative).
Primarily renal excretion; 70-80% of aprotinin is eliminated unchanged in urine within 48 hours; minor biliary/fecal elimination (<5%).
Category C
Category C
Antifibrinolytic
Antifibrinolytic